Physician profile
Alex Tsai
NPI 1740416304
$9,698.10
in general payments reported to CMS, 2019-2025
35 companies · $2,771 in 2025
The $2,771 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $933 · 2020: $1,429 · 2021: $1,128 · 2022: $502 · 2023: $1,309 · 2024: $1,626 · 2025: $2,771.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,676 · Long Term Medical Supply Or Device Loan: $29.97.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,675.55 |
| Long Term Medical Supply Or Device Loan | $29.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $1,627.28 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,581.52 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Bayer Healthcare Pharmaceuticals INC. | $1,193.73 | 2022-2025 | |
| Abbvie INC. | $938.62 | 2020-2025 | Ubrelvy, Vraylar, Qulipta |
| Novo Nordisk INC | $768.90 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $482.37 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Abbott Laboratories | $468.63 | 2021-2025 | Freestyle Libre 3, Freestyle Insulinx |
| Amarin Pharma, INC. | $435.44 | 2019-2021 | |
| Amgen INC. | $260.98 | 2020-2025 | Repatha, Otezla, Krystexxa |
| Glaxosmithkline, LLC. | $244.62 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Kowa Pharmaceuticals America, INC. | $208.96 | 2025 | Zoryve |
| Exact Sciences Corporation | $179.62 | 2023-2025 | Cologuard Collection Kit |
| Astellas Pharma US INC | $150.41 | 2023-2025 | Veozah, Myrbetriq |
| Takeda Pharmaceuticals U.S.A., INC. | $137.77 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $128.82 | 2019-2021 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $114.02 | 2020-2023 | Jardiance |
| Otsuka America Pharmaceutical, INC. | $104.95 | 2022-2024 | Rexulti |
| Janssen Pharmaceuticals, INC | $100.14 | 2019-2024 | Xarelto |
| Gilead Sciences, INC. | $74.40 | 2020-2025 | |
| Teva Pharmaceuticals USA, INC. | $64.03 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $62.97 | 2021 | |
| Axsome Therapeutics, INC. | $52.86 | 2025 | Auvelity |
| Biohaven Pharmaceutical Holding Company LTD. | $51.07 | 2022 | |
| Eisai INC. | $44.99 | 2020-2021 | |
| Clarus Therapeutics INC. | $44.92 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $32.84 | 2021-2022 | |
| Allergan, INC. | $28.93 | 2020 | |
| Xeris Pharmaceuticals, INC. | $16.87 | 2021 | |
| Qol Medical, LLC | $15.26 | 2021 | |
| Dynavax Technologies Corporation | $15.12 | 2025 | Heplisav-B |
| Grifols USA, LLC | $14.25 | 2021 | |
| Horizon Therapeutics Plc | $14.20 | 2019 | |
| Acerus Pharmaceuticals Corporation | $14.11 | 2021 | |
| Bausch Health US, LLC | $13.13 | 2020 | |
| Cranial Technologies, INC | $11.37 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alex Tsai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.